Danaher Corporation exceeded Q3 2025 expectations, reporting $6.1 billion in sales and 3% core revenue growth, driven by robust bioprocessing demand and higher-than-anticipated respiratory revenue at Cepheid. Adjusted diluted EPS rose 10% year-over-year, supported by disciplined cost management and volume leverage. While underlying market conditions remain dynamic, the company is proactively investing $175 million in productivity measures to strengthen its 2026 cost structure, targeting over 100 basis points of margin expansion. Despite cautious equipment spending linked to global policy and tariff uncertainties, the long-term outlook for biologics and monoclonal antibody production remains strong. Danaher continues to prioritize strategic M&A while utilizing share repurchases to deploy capital, maintaining a focus on innovation and operational efficiency to navigate current geopolitical pressures and drive sustainable value creation.
Sign in to continue reading, translating and more.
Open full episode in Podwise